
Sign up to save your podcasts
Or
Toby Maher joins us to discuss results of a randomised, double-blind, placebo-controlled, proof-of-concept trial of ENV-101, an oral inhibitor of the hedgehog signalling pathway, in patients with idiopathic pulmonary fibrosis.
Read the full article:
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00239-5/fulltext?dgcid=buzzsprout_icw_podcast_September_25_lanres
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
5
11 ratings
Toby Maher joins us to discuss results of a randomised, double-blind, placebo-controlled, proof-of-concept trial of ENV-101, an oral inhibitor of the hedgehog signalling pathway, in patients with idiopathic pulmonary fibrosis.
Read the full article:
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00239-5/fulltext?dgcid=buzzsprout_icw_podcast_September_25_lanres
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
2 Listeners
323 Listeners
36 Listeners
500 Listeners
368 Listeners
22 Listeners
0 Listeners
0 Listeners
2 Listeners
2 Listeners
0 Listeners
0 Listeners
0 Listeners
15,969 Listeners
0 Listeners
1 Listeners
0 Listeners
1 Listeners
0 Listeners
0 Listeners
0 Listeners
0 Listeners
0 Listeners
0 Listeners
848 Listeners
1 Listeners
0 Listeners